BMP is a venture capital investment manager providing private equity and mezzanine financing to healthcare and human life science companies. The firm focuses on startups, young businesses and spinoffs in the biotechnology, emerging pharmaceuticals, medical technology and diagnostics sectors. They invest in Switzerland and neighboring countries.BioMedInvest is a venture capital fund invested in direct equity. BMP actively scouts for investment opportunities through their network of academic contacts. They target businesses with exceptional growth potential which are driven by distinctive technologies or offering services with unique advantages over current treatments. They generally participate in the first round of financing, either as the lead investor or through syndication with private equity firms and private individuals. The firm fosters the growth of their portfolio companies through management consulting and business support services. Their exit strategies include IPO and sale to leading pharmaceutical corporations or to strategic investors.BioMedInvest II LP is a venture capital fund focused on healthcare-related investments. The fund supports early-stage private firms as well as spin-offs active in segments such as emerging pharmaceutical, biotechnology, medical technology, diagnostics or platform technologies. They look for investments primarily in Switzerland, Germany and neighboring Western Europe. The fund typically invests in a range from CHF 1 million to CHF 10 million, as lead or co-lead investor.BioMedCredit is a mezzanine fund providing growth and expansion capital to small- and mid-size innovative businesses in Switzerland offering specialized services which may not have significant scaling-up potential. They focus on firms operating in products, technologies and services, specifically in the fields of biotechnology, emerging pharmaceuticals, analytical services, biomaterials, bioengineering, bioinformatics, down-stream processing, biotechnological platform technologies, chemical products and reagents, contract R&D and manufacturing, diagnostics, drug delivery technologies, lab technologies, automation, cell culture technologies as well as medical technology. The amount invested of the portfolio firms' lifetime ranges from CHF 0.5 million to CHF 5 million.